Concepedia

Rachel Meyers

RM

Statistics

Publications

33

Citations

5.7K

H-Index

27

Active since

1969

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

University of Tennessee Health Science Center

Massachusetts Institute of Technology

St. Jude Children's Research Hospital

Le Bonheur Children's Hospital

Rachel Meyers is an author at Alnylam Pharmaceuticals (United States) specializing in life sciences, molecular biology, and rna interference.

Publications per year

1969–2024

33

Publications

33

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

Teresa Coelho, David Adams, Ana Silva et al. · New England Journal of Medicine · 2013 · 961 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +15

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso et al. · Cancer Discovery · 2013 · 699 citations

Pharmacy, Oncology, Pharmaceutics +17

ARF mediates recruitment of PtdIns-4-OH kinase-β and stimulates synthesis of PtdIns(4,5)P2 on the Golgi complex

Anna Godi, Paolo Pertile, Rachel Meyers et al. · Nature Cell Biology · 1999 · 541 citations

Life Sciences, Cell Biology, Molecular Biology +10

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

John P. DeVincenzo, Rob Lambkin‐Williams, Tom Wilkinson et al. · Proceedings of the National Academy of Sciences · 2010 · 439 citations · Full text

Life Sciences, Infectious Diseases, Molecular Medicine +17

5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

Hendrik Poeck, Robert Besch, Cornelius Maihoefer et al. · Nature Medicine · 2008 · 385 citations

Life Sciences, Molecular Biology, Oncology +13

1–5 of 33